Rallybio validates durable complement suppression with RLYB116 in Phase 1 study

Rallybio reports Phase 1 data for RLYB116 showing sustained complement inhibition. Find out what this changes for C5 therapies and what comes next.

Rallybio reports Phase 1 data for RLYB116 showing sustained complement inhibition. Find out what this changes for C5 therapies and what comes next.